A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Study acronym: AMPLIFY-2
StatusNot Yet Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Eli Lilly
363 trials monitored
See 16 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared to tirzepatide for body weight reduction in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 2 years.
Trial Details
NCT Number NCT07881458
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Obesity, Overweight, Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov